Sublingual Tirzepatide: What the Evidence Actually Shows

Quick Answer: What Sublingual Tirzepatide Is (and What Is Known About It)

*Sublingual tirzepatide is a compounded form of tirzepatide, usually a troche, dissolving tablet, or liquid drops, made to dissolve under the tongue instead of being injected. As of July 24, 2026 there is no FDA-approved sublingual or oral tirzepatide product in the United States, and no published human pharmacokinetic study establishing how much tirzepatide actually reaches the bloodstream by that route.*

The line between what is known and what is assumed:

• Known: every pivotal tirzepatide trial used a once-weekly subcutaneous injection, and FDA prescribing information for the approved products (Zepbound, Mounjaro) describes injection.
• Known: peptides the size of tirzepatide cross mucous membranes poorly. The nearest published benchmarks, all for semaglutide, run from a fraction of one percent to about one percent.
• Not known: how much tirzepatide is absorbed sublingually in humans, how consistent that absorption is, or whether any sublingual dose produces exposure comparable to the injections that were studied.

Absence of published data is not proof that something fails. It does mean nobody can honestly tell you it works. Compounded medications are not FDA-approved as final products, and any compounded medication is prescribed only if a licensed physician determines it is appropriate. We do not sell a sublingual formulation, which is part of why we can write this plainly.

How Sublingual Delivery Is Supposed to Work

The rationale is real pharmacology. Tissue under the tongue is thin, unkeratinized, and densely vascular, so a drug that crosses it enters circulation directly and skips first-pass liver metabolism. That is why sublingual nitroglycerin acts within minutes for angina, and why buprenorphine comes as a sublingual film.

The catch: molecules that succeed by this route are small, reasonably lipophilic, and effective at low doses. Tirzepatide is none of those.

• Size. Tirzepatide weighs roughly 4,813 daltons, semaglutide roughly 4,113. Passive diffusion across oral mucosa falls off sharply above a few hundred daltons.
• Structure. Peptides are hydrophilic and charged, the opposite of what helps a molecule slip through a lipid membrane.
• Enzymes and washout. Saliva and oral tissue contain peptidases, a troche sits in the mouth briefly, and swallowed saliva carries drug to the stomach, where acid and digestive enzymes degrade peptides further.

None of this makes sublingual peptide delivery impossible. Scientists work on it seriously, with permeation enhancers, mucoadhesive films, and protease inhibitors. It does put the burden of proof on anyone claiming a troche has solved it.

What the Published Evidence Actually Shows for Peptide Bioavailability

An earlier version of this topic on our site was pulled by our own compliance review for repeating absorption percentages that had no source. So here are the only numbers on this page, each cited, none of them sublingual tirzepatide in humans.

Oral semaglutide, roughly 1 percent. The approved oral semaglutide products (Rybelsus, and oral semaglutide 25 mg for weight management) absorb only with SNAC, an absorption enhancer that shields the peptide and raises local gastric pH. The published clinical pharmacology behind that platform reports absolute bioavailability on the order of 1 percent (Buckley et al., *Science Translational Medicine*, 2018). Hence the daily dosing, empty stomach, and wait before eating.

Sublingual semaglutide in rats, 0.34 percent and 0.29 percent. A single-dose study published in the *European Journal of Pharmaceutical Sciences* in 2025 compared routes in rats and reported relative bioavailability of 0.34 percent for sublingual semaglutide as a tablet and 0.29 percent as a powder, against injection. The authors framed it as proof of concept and called for human studies. Take it for what it is: an animal study, a single dose, a different molecule.

Sublingual tirzepatide in humans: no published study. We could not identify peer-reviewed human pharmacokinetic data for sublingual tirzepatide as of July 24, 2026. When a website states an absorption percentage for its sublingual tirzepatide, there is no public human study to check it against.

So where do the marketing figures come from? Usually an animal study, an unpublished supplier report, or a number copied from another marketing page. If a provider quotes a percentage, ask for the citation: journal, year, species, route. A company that has the data will send it. Same test as in our guide to evaluating whether a compounded GLP-1 is safe, and behind our breakdown of what is known about sublingual tirzepatide's needle-free cousin, the GLP-1 patch.

Why Tirzepatide Trials Used Injection

Tirzepatide's evidence base was built entirely on subcutaneous injection. SURMOUNT-1 (*New England Journal of Medicine*, 2022) and SURMOUNT-2 (*NEJM*, 2023) studied once-weekly subcutaneous tirzepatide for weight management, and the SURPASS program did the same in type 2 diabetes. FDA prescribing information for Zepbound and Mounjaro reflects that route and schedule.

The consequence matters: those results describe the injected product at the studied doses. They are not evidence about a troche, drops, or any other route. When a sublingual product is marketed beside trial data from injections, that data is doing work it was never designed to do.

Is There an FDA-Approved Oral Tirzepatide?

No. The question gets tangled because three categories get discussed as one. Status checked July 24, 2026 against the FDA's Drugs@FDA database.

1. Approved oral GLP-1 medicines that are not tirzepatide. Oral semaglutide has been approved for type 2 diabetes since 2019 as Rybelsus. Novo Nordisk announced FDA approval of oral semaglutide 25 mg (the Wegovy pill) for weight management on December 22, 2025, supported by the OASIS 4 trial. Eli Lilly announced FDA approval of orforglipron (Foundayo) on April 1, 2026, the first oral small-molecule GLP-1 receptor agonist for weight management, from the ATTAIN phase 3 program. Neither is tirzepatide, and neither is sublingual.

2. Investigational programs. Oral incretin development is active, but the leading oral program from tirzepatide's manufacturer is orforglipron, a small molecule designed from the start for oral dosing, not an oral tirzepatide. Making a peptide work by mouth has been achieved only with dedicated absorption technology.

3. Compounded sublingual or oral tirzepatide. Prepared by compounding pharmacies, not FDA-approved as final products, never reviewed for absorption or consistency.

Choosing between molecules rather than routes? Our tirzepatide vs semaglutide comparison covers the approved injectables, and our overview of sublingual and oral tirzepatide forms covers what pharmacies actually prepare.

Why an Injectable Dose Cannot Be Converted to a Sublingual Dose

You will find charts converting milligrams of injectable tirzepatide into milligrams of a sublingual product. Treat them as a warning sign: the arithmetic is not approximate, it is invalid.

A dose in milligrams means something only alongside how much of it reaches the bloodstream. Injected tirzepatide has characterized absorption described in FDA labeling. Sublingual tirzepatide has no published human absorption figure at all. Multiplying by an unknown does not produce a dose, it produces a guess with a decimal point on it. Three problems compound that:

• Variability. Where sublingual peptide absorption has been measured, the spread between individuals and doses is wide. Swallowing, saliva flow, how long the troche is held, and eating soon after all change the result.
• Formulation differences. Compounded preparations differ by pharmacy in base, excipients, enhancers, and concentration. Two products labeled the same strength are not interchangeable.
• Titration is route-specific. The step-up schedules in FDA labeling exist to manage gastrointestinal effects on a once-weekly injection. Our dosage guide explains why doses do not convert between routes.

So dosing belongs to a clinician who can see your history. Any GLP-1 medication is prescribed only if a licensed physician determines it is appropriate, and nobody should recalculate a dose from an internet table.

How Compounded Sublingual Tirzepatide Is Regulated

Compounding is legal and long established under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The two categories differ.

• 503A pharmacies prepare medications for an individual patient under a valid prescription. They are licensed by state boards, are not held to the FDA's full drug-manufacturing regulations, and their preparations are not FDA-approved.
• 503B outsourcing facilities register with the FDA, follow current good manufacturing practice requirements, and may produce batches without patient-specific prescriptions.

Two facts shape the picture. The FDA states plainly that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. And the FDA declared the tirzepatide shortage resolved in October 2024, reaffirming that determination on December 19, 2024, and declared semaglutide's resolved on February 21, 2025, ending the basis for large-scale compounding of copies of the approved drugs. Compounding for an individual patient where a prescriber documents a clinically significant difference remains permitted, and a change of route is one difference sometimes cited. Whether that fits a given patient is a clinical and legal judgment.

The practical consequence: there is no standard sublingual tirzepatide. Strength, base, and instructions vary by pharmacy, and no regulator has reviewed them for absorption.

What to Ask a Provider Who Offers a Sublingual Form

Eight questions that separate a serious operation from a storefront. Ask in writing.

1. Which pharmacy compounds it, and what is its license? Name, state license number, and whether it is a 503A pharmacy or 503B outsourcing facility. A provider who will not name the pharmacy has answered the question.
2. Can I see a certificate of analysis for my batch? Independent third-party testing for potency and, where applicable, sterility, per batch rather than occasionally.
3. Where does the active ingredient come from? A named FDA-registered facility, not the phrase "pharmaceutical grade."
4. What published data supports absorption of this formulation? Journal, year, species, route. Expect a real citation or an honest "none."
5. Who sets the dose and schedule? A named, state-licensed prescriber reviewing your history, not an algorithm assigning a plan at checkout.
6. What happens if I have side effects? How to reach a clinician, how fast, and whether that costs extra.
7. What is included in the price? Consultations, labs, shipping, dose changes, and what is billed separately.
8. How do I cancel, in writing? If cancelling requires a phone call during business hours, weigh that accordingly.

Our telehealth guide covers the other half of this checklist: questions to ask about a sublingual form and what a legitimate evaluation includes.

Sublingual, Oral, and Injectable: How the Formats Differ

Compare formats, not brands or providers. This is about routes of administration.

The row that matters is the second. For the approved formats, someone measured what happens in humans and published it. For compounded sublingual products, that measurement does not exist in public. Our GLP-1 medication list separates approved formats from compounded sublingual forms.

When to Call a Doctor

Any GLP-1 medication, by any route, can cause effects that need attention rather than waiting. Contact a clinician promptly, or seek emergency care, for:

• Severe or persistent abdominal pain, especially radiating to the back, which can signal pancreatitis
• Vomiting or diarrhea that stops you keeping fluids down, or dehydration signs such as dizziness on standing and dark urine
• Right upper abdominal pain, fever, or yellowing of the skin or eyes, which can signal gallbladder problems
• A neck lump, trouble swallowing, or persistent hoarseness. FDA labeling for tirzepatide carries a boxed warning about thyroid C-cell tumors seen in rodents, and it is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2
• Vision changes, especially with existing diabetic retinopathy
• Mouth irritation, ulceration, or persistent burning under the tongue with a sublingual preparation, since oral mucosal effects are not characterized for these products

You can report a problem with any medication to the FDA through MedWatch.

The Bottom Line

Sublingual tirzepatide is a compounded product with a plausible-sounding rationale and no published human evidence behind it. Large-peptide pharmacology argues against easy absorption under the tongue, the nearest published benchmarks are roughly 1 percent for an approved oral formulation with an absorption enhancer and a fraction of 1 percent for sublingual semaglutide in rats, and nobody has published what happens with tirzepatide in people. The trials everyone quotes studied an injection.

That does not make everyone offering a sublingual product dishonest. It does mean the format is being sold ahead of its evidence, and you are entitled to say so when a provider quotes trial data next to a troche. Ask the eight questions, insist on citations for any absorption claim, and remember that any GLP-1 medication is prescribed only if a licensed physician determines it is appropriate for you. If needle avoidance brought you here, raise it with a prescriber.

*Related guides:*

• Tirzepatide vs semaglutide
• Tirzepatide dosage chart and titration schedule
• Is compounded semaglutide safe?
• GLP-1 patches: what is actually in them
• What drives compounded tirzepatide costs
• GLP-1 medications and their forms

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Approval and regulatory statuses were checked on July 24, 2026 and can change: verify current status in the FDA's Drugs@FDA database. Sources: FDA prescribing information for Zepbound, Mounjaro, Rybelsus, and Wegovy; SURMOUNT-1 (NEJM 2022) and SURMOUNT-2 (NEJM 2023); the OASIS 4 and ATTAIN phase 3 programs; Buckley et al. (Science Translational Medicine, 2018); and a single-dose sublingual semaglutide pharmacokinetic study in rats (European Journal of Pharmaceutical Sciences, 2025). Compounded medications are not FDA-approved as final products. Individual results may vary.